Edition:
United States

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

36.31USD
16 Nov 2018
Change (% chg)

$-0.34 (-0.93%)
Prev Close
$36.65
Open
$36.44
Day's High
$37.55
Day's Low
$34.97
Volume
391,776
Avg. Vol
271,858
52-wk High
$68.05
52-wk Low
$31.50

Chart for

About

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The... (more)

Overall

Beta: --
Market Cap(Mil.): $1,972.82
Shares Outstanding(Mil.): 52.23
Dividend: --
Yield (%): --

Financials

  GBT.OQ Industry Sector
P/E (TTM): -- 79.36 29.34
EPS (TTM): -3.42 -- --
ROI: -44.26 -0.30 13.58
ROE: -45.52 -2.98 15.11

BRIEF-GBT Signs Licensing Agreement For Inclacumab To Treat Vaso-Occlusive Crisis

* GBT EXPANDS SICKLE CELL DISEASE PIPELINE WITH WORLDWIDE LICENSING AGREEMENT FOR INCLACUMAB FOR THE TREATMENT OF VASO-OCCLUSIVE CRISIS

Aug 23 2018

GBT's drug meets trial goal, investors skeptical of speedy approval

Global Blood Therapeutics Inc's sickle cell disease treatment met the main goal of a late-stage trial, but scepticism over whether the drug would get an accelerated review from health regulators pushed its shares down 12 percent.

Jun 27 2018

UPDATE 3-GBT's drug meets trial goal, investors skeptical of speedy approval

* Shares fall as much as 12 pct (Adds details from conference call, analyst comments; updates share move)

Jun 27 2018

Global Blood Therapeutics' sickle cell disease drug succeeds in trial

June 27 Global Blood Therapeutics Inc said on Wednesday its experimental drug met the main goal of a late-stage trial testing it in patients with sickle cell disease.

Jun 27 2018

Earnings vs. Estimates